Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Jani on the Effects of Tobacco and Air Pollution on Lung Cancer Mortality

June 14th 2024

Chinmay Jani, MD, discusses findings from a study evaluating the impact of tobacco use and air pollution on mortality rates in patients with lung cancer.

A Surgeon’s Perspective: How to Optimize Outcomes With Neoadjuvant Chemo/IO in Lung Cancer

June 13th 2024

Eric Vallieres, MD, FRCSC, discusses the evolving role of surgery in lung cancer treatment following the implementation of new neoadjuvant and adjuvant treatments.

Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC

June 11th 2024

Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.

Overcoming Barriers to NSCLC Biomarker Testing

June 11th 2024

Key opinion leaders delve into the challenges posed by payers, costs, out-of-pocket maximums, and the need for letters of medical necessity, while also addressing additional sources of resistance encountered in clinical practice.

Challenges of NSCLC Biomarker Testing in Clinical Practice

June 11th 2024

Zofia Piotrowska, MD, MHS, shares insights into the challenges and advantages of diagnostic testing practices at Massachusetts General Hospital, including the benefits of on-site testing, the need for less streamlined consent forms, and areas for improvement to expedite the diagnostic testing ordering process.

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

June 10th 2024

The European Commission has approved alectinib for adjuvant use in adult patients with ALK+ non–small cell lung cancer at high risk of recurrence.

FDA Grants Priority Review to Osimertinib for EGFR+ Stage III NSCLC

June 10th 2024

The FDA has granted priority review to the supplemental NDA seeking the approval of osimertinib in EGFR-mutated stage III non–small cell lung cancer.

Dr Spigel on the Efficacy of Durvalumab Consolidation Therapy in LS-SCLC

June 7th 2024

David R. Spigel, MD, discusses findings from the phase 3 ADRIATIC trial in patients with limited-stage small cell lung cancer.

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

June 4th 2024

TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC

June 4th 2024

Nivolumab plus ipilimumab and chemotherapy elicited a durable, long-term survival benefit vs chemotherapy alone in metastatic NSCLC.

Reflex Testing for Patients with Suspected Lung Cancer

June 4th 2024

Key opinion leaders highlight findings from a University of Pennsylvania study demonstrating that implementing reflex next-generation sequencing testing can reduce time-to-treatment from 19 days to 10 days, potentially leading to improved overall patient outcomes and survival rates in non-small cell lung cancer.

Biomarker Testing in Early-Stage NSCLC

June 4th 2024

Medical experts recommend that EGFR, ALK, and PD-L1 testing be performed as reflex tests for patients with early-stage non-small cell lung cancer to inform personalized treatment strategies.

Osimertinib Plus Chemotherapy Moves One Step Closer to EU Approval in EGFR+ Advanced NSCLC

June 4th 2024

The European Medicines Agency’s CHMP has recommended the approval of frontline osimertinib plus chemotherapy for EGFR-mutated non–small cell lung cancer.

Unveiling the Plenary and Gynecologic Cancer Abstracts: Drs Ramalingam and O'Malley

June 4th 2024

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC

June 3rd 2024

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

Dato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain Metastases

June 3rd 2024

Datopotamab deruxtecan demonstrated comparable intracranial activity and safety in pretreated patients with NSCLC with or without brain metastases.

Updated CheckMate 816 Data Reinforce Neoadjuvant Nivolumab/Chemo as a SOC for Resectable NSCLC

June 3rd 2024

Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.

DFS, OS Benefit Maintained With Adjuvant Atezolizumab vs BSC in Stage II/IIIA NSCLC

June 3rd 2024

Long-term DFS and OS outcomes with adjuvant atezolizumab in stage II to IIIA NSCLC were consistent with prior data from the IMpower010 trial.

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

June 3rd 2024

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

June 2nd 2024

Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.